In healthy subjects, subcutaneous injections of GLP-2 elicit a dose-related decrease in CTX-1 (a bone resorption marker), which has sparked suggestions for the use of GLP-2 as a potential osteoporosis treatment [68]. The gene discussed is GCG; the disease is osteoporosis.